Chris Tse
AbbVie (United States)(US)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research, Microtubule and mitosis dynamics, Synthesis and Characterization of Heterocyclic Compounds
Most-Cited Works
- → ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets(2013)2,976 cited
- → Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy(2015)535 cited
- → Discovery of a Potent and Selective BCL-X L Inhibitor with in Vivo Activity(2014)328 cited
- → Discovery and Development of Potent and Selective Inhibitors of Histone Methyltransferase G9a(2014)185 cited
- Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208(2013)
- → Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity(2015)150 cited
- → The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo(2011)148 cited
- → The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia(2015)94 cited
- → Discovery of 4-[(2 R ,4 R )-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2 H -chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis(2017)76 cited
- → Chemical characterization of isocyanate-protein conjugates(1979)73 cited